A5051839932- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Diverticular Disease and Complications
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Surgical Treatments
- Gastric Cancer Management and Outcomes
- Cardiac Valve Diseases and Treatments
- Colorectal Cancer Screening and Detection
- Colorectal and Anal Carcinomas
- Cardiac Imaging and Diagnostics
- Melanoma and MAPK Pathways
- Inflammatory Bowel Disease
- Cancer Treatment and Pharmacology
- Minimally Invasive Surgical Techniques
- Anorectal Disease Treatments and Outcomes
- Aortic Disease and Treatment Approaches
- Appendicitis Diagnosis and Management
- Pelvic and Acetabular Injuries
- Neuroendocrine Tumor Research Advances
- Trauma and Emergency Care Studies
City of Hope
2019-2024
City Of Hope National Medical Center
2018-2024
University of California, Irvine Medical Center
2023
Beckman Research Institute
2020
Cedars-Sinai Medical Center
2018-2019
Colorectal Surgical Associates
2015
Microsatellite instability (MSI) is a biomarker for response to immune checkpoint inhibitors (ICPIs). PD-1 in metastatic colorectal carcinoma (mCRC) with MSI-high (MSI-H) have demonstrated high disease control rate and favorable progression-free survival (PFS); however, reported rates pembrolizumab nivolumab are variable often <50%, suggesting that additional predictive biomarkers needed.
Immunotherapy combinations with activity in patients microsatellite stable (MSS) metastatic colorectal cancer need to be identified.
<h3>Importance</h3> Microsatellite stable (MSS) metastatic colorectal cancer has been historically characterized as resistant to immunotherapy. Recent studies have demonstrated limited clinical activity of programmed cell death receptor 1/programmed ligand 1 (PD-1/PD-L1) targeting in MSS cancer. The association disease the liver with treatment response not fully investigated. <h3>Objective</h3> To investigate metastases PD-1/PD-L1–targeting therapy <h3>Design, Setting, and Participants</h3>...
Metastatic colorectal cancers (MCRCs) with microsatellite stability (MSS) are resistant to immunotherapy programmed cell death protein 1 (PD-1) and death-ligand inhibitors. However, the addition of regorafenib nivolumab was recently associated a high response rate protracted progression-free survival in small cohort MSS Japanese patients metastatic cancer.
A circulating tumor DNA (ctDNA) assay (Signatera; Natera) has been marketed for use in the surveillance of resected colorectal cancer despite limited data supporting such practice.To compare a ctDNA with standard radiographic imaging and measurement carcinoembryonic antigen (CEA) levels, per National Comprehensive Cancer Network guidelines, cancer.This retrospective, single-center cohort study evaluated strategies ctDNA, imaging, CEA levels patients from September 1, 2019, to November 30,...
Abstract Background Direct comparisons between Guardant360 (G360) circulating tumor DNA (ctDNA) and FoundationOne (F1) biopsy genomic profiling in metastatic colorectal cancer (mCRC) are limited. We aim to assess the concordance across overlapping genes tested both F1 G360 patients with mCRC. Materials Methods retrospectively analyzed 75 mCRC who underwent testing. evaluated among gene mutations by three categories of patients: untreated, treated without, EGFR inhibitors, while considering...
Abstract Trial Information Click here to access other published clinical trials. Lessons Learned Radioembolization with yttrium-90 resin microspheres can be combined safely full doses of durvalumab and tremelimumab in patients metastatic colorectal cancer. Regional radioembolization did not result any hepatic or extrahepatic responses a combination tremelimumab. The lack immunomodulatory on biopsies before after treatment rules out potential role for this strategy converting “cold tumor”...
Abstract Background The prognostic implication of wild-type APC (APC-WT) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) is not well defined. Materials and Methods value was evaluated retrospectively two independent cohorts patient with MSS mCRC a confirmatory analysis from public data set Memorial Sloan Kettering Cancer Center (MSKCC). Results In comparison the APC-mutant (APC-MT) population (n = 255), APC-WT patients 86) tended to be younger (59% age &lt; 40 vs. 26%...
Limited studies have suggested that mucinous histology is associated an attenuated response to anti-epidermal growth factor receptor (EGFR) therapy.
Patients with severe aortic stenosis (AS) and an extra-large annulus (ELA) area (>683 mm
There have been conflicting reports on the predictive impact of metastatic disease sites response to checkpoint inhibitors (CPI) in microsatellite instability (MSI) colorectal cancers (mCRC). Recent studies highlighted peritoneal metastases, ascites, and liver metastases as possible indicators resistance CPI.
Currently, clinical trials with programmed death-1 (PD-1) inhibitors exclude patients preexisting autoimmune disorders such as Guillain-Barre syndrome (GBS). Therefore, the scientific literature has limited information about efficacy and safety of PD-1 in cancer disorders. Immune checkpoint can exacerbate induce severe immune-related adverse events. Here, we report case a 73-year-old female patient history GBS mismatch repair deficient metastatic colorectal who achieved durable complete...
: Class 3 MEK1 mutations disrupt the negative regulatory helix region of and drive constitutive activation both pMEK pERK that is independent RAF MEK phosphorylation. Targeting with trametinib resulted in mixed clinical responses class mutated Langerhans cell histiocytosis (LCH). The ERK inhibitor, ulixertinib, demonstrated limited anti-tumor activity non-characterized solid tumors, 2 out 4 patients experiencing stable disease (SD). Here, we present case a 52-year-old female metastatic colon...
Prior studies have resulted in conflicting conclusions on the value of SMAD4 mutations as a prognostic biomarker metastatic colorectal cancer. In this study, impact coexisting with overall survival was evaluated retrospectively 433 patients mutation found 16.2% (70/433) tumors. A systemic univariate and multivariate analysis model including age, gender, sidedness primary tumor, RAS, BRAFV600E, APC, TP53 status showed that were not associated worse prognosis (multivariate HR = 1.25, 95% CI...
Abstract Background RAS short variant (SV) mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor (EGFR) monoclonal antibody (EGFRmAb). However, the clinical implications for amplification (RASa) as a biomarker anti-EGFR therapy CRC remain ill defined. Methods Genomic analysis was performed using Foundation Medicine (FM) comprehensive genomic profiling database 37,233 cases. Clinical outcomes were assessed two independent cohorts: City...
72 Background: Microsatellite stable (MSS) metastatic colorectal cancer (mCRC) has been associated with immunotherapy resistance. However, the impact of diseases sites on clinical outcome checkpoint inhibition not be adequately investigated. Methods: Following IRB approval (14361), we performed a retrospective study to assess response and progression-free survival (PFS) PD-1 or PD-L1 based therapy in patients MSS mCRC who progressed following standard chemotherapy targeted therapy. Patients...
Abstract Background and Methods We characterized colorectal liver metastasis recurrence survival patterns after surgical resection intraoperative ablation ± hepatic arterial infusion pump (HAIP) placement. estimated of in patients undergoing contemporary multimodal treatments. Between 2017 2021, patient, tumor characteristics, data were collected. Primary outcomes included based on operative intervention. Results There 184 who underwent hepatectomy ablation. Sixty (32.6%) HAIP A total 513...
43 Background: PD-1 targeting with pembrolizumab or nivolumab leads to durable clinical benefits in patients (pts) microsatellite instability-high (MSI-H) tumors. However, 30-35% of mCRC pts MSI-H tumors will experience progressive disease (PD) as a best response when treated anti-PD1 agents, highlighting the need additional predictive biomarkers. Methods: We performed retrospective multi-center investigation evaluate impact TMB, age, gender, stage at initial presentation, pattern metastatic...
Abstract Background: We have noted that responses to the combinations of regorafenib and nivolumab (REGONIVO) or ipilimumab (RIN) were limited MSS mCRC without liver involvement. sought delineate impact non-liver metastatic sites on response these combinations. Methods: performed a single center retrospective analysis receiving REGONIVO RIN. To isolate immunotherapy disease sites, we 2-month (mo) organ specific using RECIST assessment. Results: 96 patients (Pts) (39 RIN 57 REGONIVO)...